Table 4 The reported chromatographic methods for determination of NIRMA and RITONA
Sample | Sample preparation | Detection technique | Linearity (ng/mL.) | % RSD | LOQ | Refs. |
|---|---|---|---|---|---|---|
Plasma | Protein precipitation | LC–MS/MS | 10–10,000 ng/mL for nirmatrelvir and 2–2000 ng/mL for ritonavir | ≤ 13.6 | 20 and 4 ng/mL for nirmatrelvir and ritonavir respectively | [18] |
Plasma | Protein precipitation | LC–MS/MS | 50–5000 ng/mL for nirmatrelvir and 10–1000 ng/mL for ritonavir | ≤ 14.9 | 100.0 and 20.0 ng/mL for nirmatrelvir and ritonavir respectively | [17] |
Pharmaceutical preparation and plasma | Protein precipitation | TLC | 10–50 ng/band | ≤ 0.982 | 2.106 and 1.304 ng/band for nirmatrelvir and ritonavir respectively | [30] |
Pharmaceutical preparation | N/A | HPLC–UV/VIS | 1000–20,000 ng/mL for both drugs | ≤ 0.501 | 0.60 and 0.96 µg/mL | [29] |
Plasma | SULLME | HPLC–DAD | 1000 to 20,000 ng/mL for nirmatrelvir and 200 to 20,000 ng/mL for ritonavir | ≤ 13.05 | 3 and 0.6 µg/mL | This work |